S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
3 Value Stocks Too Small For Buffett’s Portfolio
Stock market today: Asian shares are mostly higher after another set of Wall St records
Foot Locker Builds Up Another Head of Steam; Gains Imminent
Disney Stock Catches 3 Upgrades In a Single Week
Average long-term US mortgage rate falls slightly, easing borrowing costs for home shoppers
Walgreens books hefty charge as the drugstore chain adjusts the value of struggling clinics
Algeria's government pushes staples to subsidized markets to stave off Ramadan shortages
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
3 Value Stocks Too Small For Buffett’s Portfolio
Stock market today: Asian shares are mostly higher after another set of Wall St records
Foot Locker Builds Up Another Head of Steam; Gains Imminent
Disney Stock Catches 3 Upgrades In a Single Week
Average long-term US mortgage rate falls slightly, easing borrowing costs for home shoppers
Walgreens books hefty charge as the drugstore chain adjusts the value of struggling clinics
Algeria's government pushes staples to subsidized markets to stave off Ramadan shortages
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
3 Value Stocks Too Small For Buffett’s Portfolio
Stock market today: Asian shares are mostly higher after another set of Wall St records
Foot Locker Builds Up Another Head of Steam; Gains Imminent
Disney Stock Catches 3 Upgrades In a Single Week
Average long-term US mortgage rate falls slightly, easing borrowing costs for home shoppers
Walgreens books hefty charge as the drugstore chain adjusts the value of struggling clinics
Algeria's government pushes staples to subsidized markets to stave off Ramadan shortages
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
3 Value Stocks Too Small For Buffett’s Portfolio
Stock market today: Asian shares are mostly higher after another set of Wall St records
Foot Locker Builds Up Another Head of Steam; Gains Imminent
Disney Stock Catches 3 Upgrades In a Single Week
Average long-term US mortgage rate falls slightly, easing borrowing costs for home shoppers
Walgreens books hefty charge as the drugstore chain adjusts the value of struggling clinics
Algeria's government pushes staples to subsidized markets to stave off Ramadan shortages
NASDAQ:AEZS

Aeterna Zentaris (AEZS) Stock Price, News & Analysis

$2.19
+0.11 (+5.29%)
(As of 03/28/2024 ET)
Today's Range
$2.01
$2.19
50-Day Range
$1.71
$2.19
52-Week Range
$1.36
$3.38
Volume
49,615 shs
Average Volume
25,433 shs
Market Capitalization
$10.64 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$15.00

Aeterna Zentaris MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
584.9% Upside
$15.00 Price Target
Short Interest
Healthy
0.60% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.10mentions of Aeterna Zentaris in the last 14 days
Based on 9 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($3.22) to ($3.37) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.69 out of 5 stars

Medical Sector

762nd out of 939 stocks

Pharmaceutical Preparations Industry

359th out of 441 stocks

AEZS stock logo

About Aeterna Zentaris Stock (NASDAQ:AEZS)

Aeterna Zentaris Inc., a specialty biopharmaceutical company, engages in developing and commercializing therapeutics and diagnostic tests. Its lead product is Macrilen (macimorelin), an orally available peptidomimetic ghrelin receptor (GHSR-1a) agonist that stimulates the secretion of growth hormone by binding to the GHSR-1a for the diagnosis of adult growth hormone deficiency and childhood-onset growth hormone deficiency, as well as oncology indications; and AEZS-150, a delayed clearance parathyroid hormonefusion polypeptide that is in preclinical trail for the treatment of hypoparathyroidism in adults. Aeterna Zentaris Inc. has a license agreement with University of Wuerzburg to research, develop, manufacture, and sell a potential COVID-19 vaccine; development, manufacture, and commercialization of the treatment for neuromyelitis optica spectrum disorder; and for pre-clinical development towards the potential treatment of Parkinson's disease. It also has a license agreement with Consilient Health Ltd. and NK MEDITECH Ltd. for the development and commercialization of macimorelin in the Republic of Korea; a distribution and commercialization agreement with Er-Kim Pharmaceuticals Bulgaria EOOD for the commercialization of macimorelin for the diagnosis of growth hormone deficiency in children and adults in Turkey and some non-European Union Balkan countries; as well as The University of Sheffield, the United Kingdom for the research, development, manufacture, and commercialization of parathyroid hormone fusion polypeptides for the treatment of primary hypoparathyroidism. Aeterna Zentaris Inc. was incorporated in 1990 and is headquartered in Summerville, South Carolina.

AEZS Stock Price History

AEZS Stock News Headlines

Trump’s “Tax Free” Retirement Strategy
Since 1924 — over one hundred years — the US dollar has lost nearly 18x its value. In other words, a dollar back then would buy $17.82 worth of goods in today's money. If you're planning on retiring any time soon…This poses a real problem.
Aeterna Zentaris Inc. (NASDAQ:AEZS) Short Interest Update
AEterna Zentaris: Q4 Earnings Insights
Trump’s “Tax Free” Retirement Strategy
Since 1924 — over one hundred years — the US dollar has lost nearly 18x its value. In other words, a dollar back then would buy $17.82 worth of goods in today's money. If you're planning on retiring any time soon…This poses a real problem.
Aeterna Zentaris Inc.
AEterna Zentaris Inc AEZS
Aeterna Zentaris GAAP EPS of -$0.85
Closing Bell: Aeterna Zentaris Inc down on Monday (AEZS)
Closing Bell: Aeterna Zentaris Inc flat on Tuesday (AEZS)
H.C. Wainwright Keeps Their Buy Rating on Aeterna Zentaris (AEZS)
See More Headlines
Receive AEZS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Aeterna Zentaris and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/04/2021
Today
3/28/2024
Next Earnings (Estimated)
5/14/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:AEZS
Employees
11
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$15.00
High Stock Price Target
$15.00
Low Stock Price Target
$15.00
Potential Upside/Downside
+584.9%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

Net Income
$-22,730,000.00
Net Margins
-340.56%
Pretax Margin
-340.56%

Debt

Sales & Book Value

Annual Sales
$5.64 million
Book Value
$7.37 per share

Miscellaneous

Free Float
4,851,000
Market Cap
$10.64 million
Optionable
No Data
Beta
1.56

Social Links

A Guide To High-Short-Interest Stocks Cover

MarketBeat's analysts have just released their top five short plays for April 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.

Get This Free Report

Key Executives

  • Dr. Klaus Paulini Ph.D.
    President, CEO & Executive Director
  • Mr. Giuliano La Fratta
    Senior VP of Finance & CFO
  • Dr. Michael Teifel Ph.D.
    Senior VP of Non-Clinical Development & Chief Scientific Officer
  • Dr. Nicola Ammer M.D.
    Chief Medical Officer & Senior VP of Clinical Development
  • Dr. Matthias Gerlach
    Senior Vice President Manufacturing & Supply Chain

AEZS Stock Analysis - Frequently Asked Questions

Should I buy or sell Aeterna Zentaris stock right now?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Aeterna Zentaris in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" AEZS shares.
View AEZS analyst ratings
or view top-rated stocks.

What is Aeterna Zentaris' stock price target for 2024?

1 brokers have issued 12 month price targets for Aeterna Zentaris' shares. Their AEZS share price targets range from $15.00 to $15.00. On average, they expect the company's stock price to reach $15.00 in the next year. This suggests a possible upside of 584.9% from the stock's current price.
View analysts price targets for AEZS
or view top-rated stocks among Wall Street analysts.

How have AEZS shares performed in 2024?

Aeterna Zentaris' stock was trading at $1.86 on January 1st, 2024. Since then, AEZS stock has increased by 17.7% and is now trading at $2.19.
View the best growth stocks for 2024 here
.

Are investors shorting Aeterna Zentaris?

Aeterna Zentaris saw a increase in short interest in March. As of March 15th, there was short interest totaling 29,200 shares, an increase of 46.0% from the February 29th total of 20,000 shares. Based on an average daily trading volume, of 16,800 shares, the short-interest ratio is presently 1.7 days. Currently, 0.6% of the shares of the stock are sold short.
View Aeterna Zentaris' Short Interest
.

When is Aeterna Zentaris' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 14th 2024.
View our AEZS earnings forecast
.

How were Aeterna Zentaris' earnings last quarter?

Aeterna Zentaris Inc. (NASDAQ:AEZS) released its earnings results on Thursday, November, 4th. The biopharmaceutical company reported ($0.25) EPS for the quarter, beating the consensus estimate of ($0.50) by $0.25. The biopharmaceutical company had revenue of $0.60 million for the quarter, compared to analyst estimates of $0.60 million. Aeterna Zentaris had a negative net margin of 340.56% and a negative trailing twelve-month return on equity of 49.10%.

When did Aeterna Zentaris' stock split?

Shares of Aeterna Zentaris reverse split on Thursday, July 21st 2022. The 1-25 reverse split was announced on Thursday, July 21st 2022. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, July 21st 2022. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split.

What other stocks do shareholders of Aeterna Zentaris own?
Who are Aeterna Zentaris' major shareholders?

Aeterna Zentaris' stock is owned by a variety of institutional and retail investors. Top institutional investors include Citadel Advisors LLC (0.00%) and Concourse Financial Group Securities Inc. (0.00%).

How do I buy shares of Aeterna Zentaris?

Shares of AEZS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:AEZS) was last updated on 3/29/2024 by MarketBeat.com Staff

From Our Partners